News
TraceLink Adds Industry Visionaries to Discuss Machine Learning, Artificial Intelligence, Big Data and Patient Engagement at FutureLink Munich
TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held...
News
Oxford Genetics announces new online customer portal for custom research services
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced the launch of a new online customer portal designed to enable customers to better monitor project progress and track communications. ...
News
Boehringer Ingelheim R&D pushes to transcend disease boundaries
Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has...
News
Tjoapack invests in blistering capabilities
Global contract packaging organisation (CPO), Tjoapack has invested in its blistering capacity, adding a new line that will be equipped with late-stage customisation printing capabilities. Expected to be operational by the end of Q3 2018, the...
News
CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP(R)Go technology
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor...
News
The Swiss Biotech Association Honors Major Industry Achievements with Swiss Biotech Success Stories
On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the...
News
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease. Biogen will...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read